Logo

QSI

Quantum-Si incorporated

QSI

Quantum-Si incorporated • NASDAQ
$1.42 ▲ 4.81% (+0.07)
Market Cap $276.71 M
52w High $5.77
52w Low $0.95
Dividend Yield 0%
P/E -2.11
Volume 2.46M
Outstanding Shares 195.55M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $552K ▼ $39.967M ▲ $-35.703M ▼ -6.468K% ▼ $-0.17 ▼ $-34.511M ▼
Q2-2025 $591K ▼ $30.471M ▲ $-28.836M ▼ -4.879K% ▼ $-0.16 ▼ $-25.567M ▼
Q1-2025 $842K ▼ $25.598M ▼ $-19.189M ▲ -2.279K% ▲ $-0.11 ▲ $-24.195M ▲
Q4-2024 $1.192M ▲ $31.287M ▲ $-33.121M ▼ -2.779K% ▲ $-0.23 ▼ $-29.683M ▼
Q3-2024 $787K $28.455M $-25.313M -3.216K% $-0.18 $-26.93M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $225.844M ▲ $260.127M ▲ $24.968M ▼ $235.159M ▲
Q2-2025 $214.211M ▼ $254.406M ▼ $33.423M ▲ $220.983M ▼
Q1-2025 $232.601M ▲ $271.222M ▲ $24.302M ▼ $246.92M ▲
Q4-2024 $209.603M ▲ $247.871M ▲ $32.451M ▲ $215.42M ▲
Q3-2024 $196.344M $236.454M $25.934M $210.52M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-35.703M ▼ $-32.019M ▼ $-6.205M ▼ $46.954M ▲ $8.722M ▲ $-32.919M ▼
Q2-2025 $-28.836M ▼ $-20.197M ▲ $5.035M ▲ $41K ▼ $-15.105M ▼ $-20.524M ▲
Q1-2025 $-19.189M ▲ $-26.154M ▼ $-34.174M ▼ $48.374M ▲ $-11.948M ▼ $-27.461M ▼
Q4-2024 $-33.121M ▼ $-22.881M ▲ $-5.925M ▼ $35.794M ▲ $6.973M ▲ $-24.316M ▼
Q3-2024 $-25.313M $-23.153M $5.87M $2K $-17.284M $-24.128M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲
Service
Service
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Income statement Quantum-Si is still essentially pre‑revenue over the five-year period shown, so the business is being built ahead of meaningful sales. The company has reported steady operating and net losses each year, which likely reflect ongoing spending on research, product development, and commercialization rather than poor performance of a mature product line. Losses per share have improved somewhat over time but remain significant, underscoring that profitability is still a long way off and will depend heavily on how quickly the new platforms gain adoption and whether the company can scale recurring consumables revenue over time.

Balance Sheet

Balance Sheet Balance sheet The balance sheet shows a classic early-stage biotech-like profile: sizeable assets relative to its small revenue base, primarily driven by cash and investments, with very little debt. However, total assets and shareholders’ equity have been drifting down as cumulative losses eat into the capital base. The company remains in a net cash position, which is a positive, but the gradual decline in cash and equity highlights the importance of controlling the burn rate and eventually converting the installed base of instruments into a more self-sustaining business. Any delay in commercialization or fundraising could matter more over time as this cushion shrinks.

Cash Flow

Cash Flow Cash flow Cash flow from operations has been consistently negative, reflecting the ongoing cash burn to fund R&D, product launches, and overhead in the absence of material revenue. Free cash flow is similarly negative, though capital spending is relatively modest, suggesting most cash consumption comes from people, trials, and commercialization activities rather than heavy manufacturing build‑out. Management has indicated that the current cash position is expected to support operations for several more years, but that runway ultimately depends on spending discipline and how quickly revenue ramps. Investors should view this as a “funded but not yet self-funding” story, with meaningful execution risk if growth or future capital access disappoints.

Competitive Edge

Competitive Edge Competitive position Quantum-Si is trying to carve out a distinct niche by bringing semiconductor-based, single-molecule protein sequencing to benchtop instruments, aiming to make advanced proteomics more accessible and easier to use than traditional mass spectrometry. Its moat rests on first-mover status in this style of protein sequencing, a substantial patent portfolio, and a vertically integrated model that ties instruments, consumables, and cloud software into one ecosystem. Partnerships with established players for distribution and with technology firms for data analysis strengthen this position. That said, the company is still small and relatively unproven commercially, competing in a field that includes very large, well-funded life science tools companies and other emerging sequencing innovators, so its long-term competitive strength will depend on real-world performance, user adoption, and how quickly it can build a base of published scientific work around its platform.

Innovation and R&D

Innovation and R&D Innovation & R&D Innovation is clearly the core of Quantum-Si’s story. The company has built a novel “time-domain” single-molecule protein sequencing approach using semiconductor chips, with real-time detection and potential advantages in ease of use and sensitivity to protein modifications. It has already launched the Platinum and Platinum Pro instruments, plus associated kits and analysis software, and is working on a more powerful next-generation system, Proteus, with ambitious performance targets. The roadmap also includes upgraded chemistry and new bioinformatics tools to broaden applications. This R&D intensity is a major strength and differentiator, but it also introduces execution risk: timelines can slip, technical hurdles can appear, and customer demand for entirely new workflows is uncertain. The value of this innovation will ultimately be judged by how widely the instruments are adopted and how central they become to everyday proteomics research.

Summary

Summary Quantum-Si is a high-risk, high-upside early-stage life science tools company: heavy on innovation and promise, light so far on revenue and profits. Financially, it operates with ongoing losses, negative cash flow, and a gradually shrinking but still meaningful cash cushion, typical for a company commercializing a new platform. Strategically, it targets an important emerging area—routine protein sequencing—with technology that could meaningfully lower the barriers to advanced proteomics and create a recurring, ecosystem-style business if adoption takes off. The main opportunities lie in converting its scientific and engineering lead into widespread market use, growing recurring consumables revenue, and leveraging partnerships. The main risks center around commercialization pace, competitive responses from larger players, technical and timeline execution on its roadmap, and continued dependence on external capital until the business scales.

NEWS

November 20, 2025 · 8:00 AM UTC

Quantum-Si Highlights Significant Development Advancements for Proteus™ and Industry Leading Technology Pipeline at Investor & Analyst Day

Read more

November 19, 2025 · 8:00 AM UTC

Quantum-Si to Highlight Significant Proteus™ Platform Development Progress and Provide Insights into the Company's Industry Leading Technology Pipeline at Investor & Analyst Day

Read more

November 5, 2025 · 4:05 PM UTC

Quantum-Si Reports Third Quarter 2025 Financial Results

Read more

October 20, 2025 · 8:00 AM UTC

Quantum-Si to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Read more

October 13, 2025 · 8:00 AM UTC

Quantum-Si to Report Third Quarter 2025 Financial Results on November 5, 2025

Read more